Prime medicine reports second quarter 2023 financial results and provides business updates

-- presented new preclinical data demonstrating ability of prime editing to correct causative mutation of cgd and highlighting ability of passige™ platform to multiplex edit car-t cells at asgct annual meeting -- -- entered strategic collaboration with cimeio therapeutics; multiplexing cimeio's shielded variants with therapeutic edits may meaningfully expand reach of prime editing --
PRME Ratings Summary
PRME Quant Ranking